Evidence of Aβ‐ and transgene‐dependent defects in ERK‐CREB signaling in Alzheimer’s models
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Extracellular‐signal regulated kinase (ERK) signaling is critical for memory and tightly regulated by acute environmental stimuli. In Alzheimer disease transgenic models, active ERK is shown to first be increased, then later reduced, but whether these baseline changes reflect disruptions in ERK signaling is less clear. We investigated the influence of the familial Alzheimer’s disease transgene APP sw and β‐amyloid peptide (Aβ) immunoneutralization on cannulation injury‐associated (i.c.v. infusion) ERK activation. At both 12 and 22 months of age, the trauma‐associated activation of ERK observed in Tg− mice was dramatically attenuated in Tg+. In cortices of 22‐month‐old non‐infused mice, a reduction in ERK activation was observed in Tg+, relative to Tg− mice. Intracerebroventricular (i.c.v.) anti‐Aβ infusion significantly increased phosphorylated ERK, its substrate cAMP‐response element‐binding protein (CREB) and a downstream target, the NMDA receptor subunit. We also demonstrated that Aβ oligomer decreased active ERK and subsequently active CREB in human neuroblastoma cells, which could be prevented by oligomer immunoneutralization. Aβ oligomers also inhibited active ERK and CREB in primary neurons, in addition to reducing the downstream post‐synaptic protein NMDA receptor subunit. These effects were reversed by anti‐oligomer. Our data strongly support the existence of an APP sw transgene‐dependent and Aβ oligomer‐mediated defect in regulation of ERK activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 2×
“Recently, soluble Ab oligomers, including dimers, trimers, and dodecamers (12- mer or Ab*56) have been proposed as key forms of Ab causing cognitive deficits in animal models (Cleary et al. 2005; Lesne et al. 2006).”
BackgroundRetractedCommon structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Self-citationMucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 1×
“Some AD transgenic mouse models show significant cognitive dysfunction and synaptic damage but have no insoluble Ab deposits (Kumar-Singh et al. 2000; Mucke et al. 2000).”
BackgroundRegulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530 · cited 1×
“Soluble Ab concentrations predict synaptic changes (Lue et al. 1999) and correlate with the severity of dementia in AD patients (McLean et al. 1999).”
BackgroundYing, S.-W., Futter, M., Rosenblum, K., Webber, M. J., Hunt, S. P., Bliss, T. V. P., & Bramham, C. R. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01532.2002 · Cited by 784
IRIZARRY, M. C., MCNAMARA, M., FEDORCHAK, K., HSIAO, K., & HYMAN, B. T. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199709000-00002 · Cited by 649
Self-Assembly of Aβ 1 - 42 into Globular Neurotoxins
Chromy, B. A., Nowak, R. J., Lambert, M. P., Viola, K. L., Chang, L., Velasco, P. T., Jones, B. W., Fernandez, S. J., Lacor, P. N., Horowitz, P., et al. (2003) · Biochemistry · doi:10.1021/bi030029q · Cited by 522 · cited 1×
“Trophic factors are one possibility because subtoxic levels of Ab oligomers have been reported to blunt the ERK/CREB response to trophic factors including nerve growth factor (Chromy et al. 2003) and brain derived neurotrophic factor (Tong et al. 2004).”
BackgroundPhenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology
Frautschy, S. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00300-1 · Cited by 514
Self-citationAmyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo
Klyubin, I., Walsh, D. M., Lemere, C. A., Cullen, W. K., Shankar, G. M., Betts, V., Spooner, E. T., Jiang, L., Anwyl, R., Selkoe, D. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1234 · Cited by 489 · cited 5×
“Antibody-mediated Ab oligomer reduction can correct defects in synaptic plasticity (Klyubin et al. 2005) and reduce tau phosphorylation (Klyubin et al.”
BackgroundInfluentialDineley, K. T., Westerman, M., Bui, D., Bell, K., Ashe, K. H., & Sweatt, J. D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-12-04125.2001 · Cited by 462 · cited 7×
“In vitro, it has been demonstrated that sustained ERK activation is related to cell death after Ab treatment in neurons and PC12 cells (Dineley et al. 2001; Jang and Surh 2005).”
BackgroundResultInfluentialGong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., & Arancio, O. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22831 · Cited by 442 · cited 1×
“They are relevant to cognitive function because in bigenic mutant APP · presenlin 1 transgenic mice, increasing cAMP/protein kinase A (PKA)/ CREB signaling with rolipram ameliorated deficits in LTP and cognitive function (Gong et al. 2004).”
BackgroundZhao, L., Teter, B., Morihara, T., Lim, G. P., Ambegaokar, S. S., Ubeda, O. J., Frautschy, S. A., & Cole, G. M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2860-04.2004 · Cited by 329
Self-citationRole of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease
Zhao, L., Ma, Q.-L., Calon, F., Harris-White, M. E., Yang, F., Lim, G. P., Morihara, T., Ubeda, O. J., Ambegaokar, S., Hansen, J. E., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1630 · Cited by 317 · cited 3×
“…therapeutic strategies targeting Ab oligomer by highly specific anti-Ab oligomer antibodies or drugs to limit dysregulation of multiple memory-related signaling pathways, including oligomer sensitive NMDAR/ ERK/CREB, Akt/GSK3b/ptau (Ma et al. 2006), and PAK/ LIMK/cofilin/drebrin (Zhao et al. 2006).”
BackgroundSelf-citationNMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation
Amadoro, G., Ciotti, M. T., Costanzi, M., Cestari, V., Calissano, P., & Canu, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511065103 · Cited by 243 · cited 1×
“Although transient ERK activation plays important roles in memory-related processes, persistent activation can mediate NMDA-related excitotoxicity (Amadoro et al. 2006).”
BackgroundTong, L., Balazs, R., Thornton, P. L., & Cotman, C. W. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5463-03.2004 · Cited by 221
Brendza, R. P., Bacskai, B. J., Cirrito, J. R., Simmons, K. A., Skoch, J. M., Klunk, W. E., Mathis, C. A., Bales, K. R., Paul, S. M., Hyman, B. T., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23269 · Cited by 190 · cited 1×
“(2007) 103, 1594–1607 No claim to original US government works recovery of amyloid-associated neuritic dystrophy in APP mutant transgenic mice (Brendza et al. 2005).”
BackgroundMishizen-Eberz, A. J., Rissman, R. A., Carter, T. L., Ikonomovic, M. D., Wolfe, B. B., & Armstrong, D. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.09.016 · Cited by 156 · cited 2×
“A reduction in specific NMDAR subunits, notably NR2B, occurs in AD patients and correlates with cognitive deficits (Greenamyre et al. 1987; Mishizen-Eberz et al. 2004).”
BackgroundMa, Q., Lim, G. P., Harris‐White, M. E., Yang, F., Ambegaokar, S. S., Ubeda, O. J., Glabe, C. G., Teter, B., Frautschy, S. A., & Cole, G. M. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20734 · Cited by 126 · cited 8×
“Intracerebroventricular infusion of monoclonal anti-Ab antibody (IgG2b, 10G4) as anti-Ab1–15 and control IgG2b were previously described (Ma et al. 2006).”
BackgroundMethodSelf-citationSheng, J. G., Price, D. L., & Koliatsos, V. E. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09794.2002 · Cited by 124
Johnson-Farley, N. N., Travkina, T., & Cowen, D. S. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.094433 · Cited by 63
Cited by
Molecular mechanisms of neurodegeneration in Alzheimer's disease
Crews, L., & Masliah, E. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq160 · Cited by 772
Sakamoto, K., Karelina, K., & Obrietan, K. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07080.x · Cited by 543
The role of CREB signaling in Alzheimer’s disease and other cognitive disorders
Saura, C. A., & Valero, J. (2011) · revneuro · doi:10.1515/rns.2011.018 · Cited by 312
Caccamo, A., Maldonado, M. A., Bokov, A. F., Majumder, S., & Oddo, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012851108 · Cited by 249
Nakajima, A., & Ohizumi, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143380 · Cited by 235
“Aβ oligomers also inhibit ERK and CREB activation in primary hippocampal neurons [68].”
Background
Metadata
- Authors
- Ma, Q., Harris‐White, M. E., Ubeda, O. J., Simmons, M., Beech, W., Lim, G. P., Teter, B., Frautschy, S. A., & Cole, G. M.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2007-08-03
- Volume
- 103
- Issue
- 4
- Pages
- 1594-1607
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2119875949
- Cited by
- 106
- References
- 22
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.